Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

In advanced non-small-cell lung cancer with EGFR mutations, amivantamab-lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher.

Saved in:

Bibliographic Details
Main Authors:	Yang, James Chih-Hsin (Author) , Lu, Shun (Author) , Hayashi, Hidetoshi (Author) , Felip, Enriqueta (Author) , Spira, Alexander I. (Author) , Girard, Nicolas (Author) , Kim, Yu Jung (Author) , Lee, Se-Hoon (Author) , Ostapenko, Yurii (Author) , Danchaivijitr, Pongwut (Author) , Liu, Baogang (Author) , Alip, Adlinda (Author) , Korbenfeld, Ernesto (Author) , Dias, Josiane Mourão (Author) , Besse, Benjamin (Author) , Passaro, Antonio (Author) , Lee, Ki-Hyeong (Author) , Xiong, Hailin (Author) , How, Soon-Hin (Author) , Cheng, Ying (Author) , Chang, Gee-Chen (Author) , Yoshioka, Hiroshige (Author) , Thomas, Michael (Author) , Nguyen, Danny (Author) , Ou, Sai-Hong Ignatius (Author) , Mukhedkar, Sanjay (Author) , Prabhash, Kumar (Author) , D’Arcangelo, Manolo (Author) , Alatorre-Alexander, Jorge (Author) , Limón, Juan Carlos Vázquez (Author) , Alves, Sara (Author) , Stroyakovskiy, Daniil (Author) , Peregudova, Marina (Author) , Şendur, Mehmet Ali Nahit (Author) , Yazici, Ozan (Author) , Califano, Raffaele (Author) , Calderón, Vanesa Gutiérrez (Author) , Marinis, Filippo de (Author) , Kim, Sang-We (Author) , Gadgeel, Shirish M. (Author) , Owen, Scott (Author) , Xie, John (Author) , Sun, Tao (Author) , Mehta, Jaydeep (Author) , Venkatasubramanian, Raja (Author) , Ennis, Mariah (Author) , Fennema, Elizabeth (Author) , Daksh, Mahesh (Author) , Roshak, Amy (Author) , Man, Julie (Author) , Knoblauch, Roland E. (Author) , Bauml, Joshua M. (Author) , Baig, Mahadi (Author) , Shah, Sujay (Author) , Sethi, Seema (Author) , Cho, Byoung C. (Author)
Format:	Article (Journal)
Language:	English
Published:	September 7, 2025
In:	The New England journal of medicine Year: 2025, Volume: 393, Issue: 17, Pages: 1681-1693
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2503001
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2503001 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2503001
Author Notes:	J.C.-H. Yang, S. Lu, H. Hayashi, E. Felip, A.I. Spira, N. Girard, Y.J. Kim, S.-H. Lee, Y. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E. Korbenfeld, J. Mourão Dias, B. Besse, A. Passaro, K.-H. Lee, H. Xiong, S.-H. How, Y. Cheng, G.-C. Chang, H. Yoshioka, M. Thomas, D. Nguyen, S.-H.I. Ou, S. Mukhedkar, K. Prabhash, M. D’Arcangelo, J. Alatorre-Alexander, J.C. Vázquez Limón, S. Alves, D. Stroyakovskiy, M. Peregudova, M.A.N. Şendur, O. Yazici, R. Califano, V. Gutiérrez Calderón, F. de Marinis, S.-W. Kim, S.M. Gadgeel, S. Owen, J. Xie, T. Sun, J. Mehta, R. Venkatasubramanian, M. Ennis, E. Fennema, M. Daksh, A. Roshak, J. Man, R.E. Knoblauch, J.M. Bauml, M. Baig, S. Shah, S. Sethi and B.C. Cho, for the MARIPOSA Investigators

Description
Summary:	In advanced non-small-cell lung cancer with EGFR mutations, amivantamab-lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher.
Item Description:	Online verfügbar: 06. September 2026 Gesehen am 06.02.2026
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2503001